Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;148(8):2650-2657.
doi: 10.1093/brain/awaf135.

Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy

Affiliations

Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy

Blas Couto et al. Brain. .

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by four-repeat (4R) tau protein deposition. The substantia nigra (SN) and midbrain tegmentum nuclei (MBT) are consistently affected. Lymphocyte infiltrates are scarce in the brains of patients with neurodegenerative diseases, although a few reports have described their presence in the α-synucleinopathy Parkinson's disease (PD). To evaluate the cytotoxic T-cell response, serial sections spanning 120 μm of the SN were immunostained consecutively for phosphorylated tau (p-tau, AT8) or α-synuclein, cytotoxic T-cell marker and microglia marker HLA-DR. Sections were analysed with stereology software in 9 patients with PSP, 10 with PD and 6 healthy controls. We semiquantitatively scored CD8-positive cells in further brain regions. CD8 lymphocyte cell counts and microglial activation in the SN were higher in PSP than PD and controls. Furthermore, T-cell/neuron contact was observed in PSP. In multivariate models, CD8 counts were not predicted by disease duration, younger age at death or the amount of p-tau pathology. The SN and midbrain tegmentum showed more CD8 cells than the cortex. A more prominent nigral cytotoxic T-cell response in PSP than PD supports the suggestion that p-tau neuropathology in PSP might have potential relationships with autoimmune mechanisms.

Keywords: T-lymphocyte; inflammation; neuropathology; progressive supranuclear palsy; tau.

PubMed Disclaimer

Conflict of interest statement

B.C. reports funding from CurePSP Foundation and Alzheimer's Association research and fellowship grants, no other personal fees. S.L.F. receives funding from the National Health and Medical Research Council, Australia outside the submitted work. C.F. was supported by an Edmond J. Safra Fellowship in Movement Disorders funded by the Michael. J. Fox Foundation for Parkinson Research. S.H.F. has received clinic support from the Edmond J, Safra Foundation for Parkinson Research, Parkinson Foundation and the Toronto Western and General Foundation; research funding from the Michael J. Fox Foundation for Parkinson Research, NIH (Dystonia Coalition); Parkinson Canada; honoraria from the International Parkinson and Movement Disorder Society; Site PI for Clinical Trials for Alexion, Biotie, Consultancy/Speaker fees from Abbvie, Bial, Ipsen, Sunovion; Paladin; and royalties from Oxford University Press. M.C.T. receives funding from NIH, Weston Brain Foundation, Tanenbaum Institute for Research in Science of Sport, Canadian Institutes of Health Research, and in-kind funding from Roche; she has served as an advisor to Eisai, Lilly and Novo Nordisk; she conducts clinical trials for Biogen, Anavex, Janssen, Novo Nordisk, Merck, Green Valley, UCB. A.E.L. has served as an advisor for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB; received honoraria from Sun Pharma, and AbbVie; received grants from Brain Canada, Canadian Institutes of Health Research, Edmond J. Safra Philanthropic Foundation, Michael J. Fox Foundation, Parkinson Foundation, and Parkinson Canada; received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. G.G.K. reports personal fees from Parexel, other funding from Rossy Family Foundation, from Edmond Safra Foundation, grants from Krembil Foundation, MSA Coalition, Michael J. Fox Foundation, Parkinson Canada, NIH, Canada Foundation for Innovation, and Ontario Research Fund outside the submitted work; in addition, G.G.K. has a shared patent for 5G4 Synuclein antibody and a pending patent for Diagnostic assays for movement disorders (18/537,455), and received royalties from Wiley, Cambridge, and Elsevier publishers. The remaining authors report no competing interests.

Figures

Figure 1
Figure 1
Differences in CD8-cell counts between conditions and regions. Density of CD8 cell infiltrates in the substantia nigra (SN) of progressive supranuclear palsy (PSP), Parkinson's disease (PD) and control (CO) subjects (A). CD8 cells in PSP and PD according to disease duration subgroups: benign (PSP >8 years, PD >12 years) and malignant (PSP <7 years, PD <11 years) courses (B). High magnification of the midbrain in case PSP-6 showing (blue-stained) CD8 infiltrates including lymphocytes in close proximity to the neuronal cell membrane (C). Semiquantitative scoring (0–3; n/a = not available) and heat mapping of parenchymal and perivascular CD8-cell-infiltrates in PSP-specific regions for nine PSP cases and five controls; note that only five control cases where most of the brain regions were available were included (D). CD8-cell count in red nucleus/superior cerebellar peduncle (RN/SCP) and midbrain tegmentum (MBT) in PSP (E); note that 15 samples were used for RN/SCP, since three cases had bilateral tissue available, which were all counted. CD8-cell infiltrates in the SN subregions annotated for PSP and PD (F). Note that in subregions, higher values than the mean of the summarized data plotted for the whole SN can be observed. STN = subthalamic nucleus; STR = striatum; GP = globus pallidus; MOT = motor cortex.
Figure 2
Figure 2
Regional distribution of CD8-positive cells. Immunohistochemistry for CD8-positive cells (brown) in control (CO) (A, D, G, J and M) and two cases with progressive supranuclear palsy (PSP) (B, C, E, F, H, I, K, L, N and O) in the substantia nigra (AC), red nucleus/superior cerebellar peduncle (DF), subthalamic nucleus (GI), globus pallidus (JL) and motor cortex (MO). Note the more prominent CD8 cells in PSP, including CD8 cells surrounding neurons (B). Arrowheads indicate parenchymal and arrows perivascular CD8 cells. Scale bar in A = 120 μm for all images except B, where it represents 15 μm.
Figure 3
Figure 3
Microglial load under different conditions. Mean HLA-DR (microglia) immunoreactivity area in the substantia nigra (SN) of progressive supranuclear palsy (PSP), Parkinson's disease (PD) and control (CO) samples (A). Mean microglia immunoreactivity area in SN according to disease duration subgroups: benign (PSP >8 years, PD >12 years) and malignant (PSP <7 years, PD <11 years) (B). Mean microglia immunoreactivity area in SN subregions of PSP and PD, for microglia detection (C). Note that in subregions, higher values than the mean of the summarized data plotted for the whole SN can be observed.

Similar articles

Cited by

References

    1. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99–119. - PMC - PubMed
    1. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001;60:647–657. - PubMed
    1. Malpetti M, Swann P, Tsvetanov KA, et al. Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration. Brain. 2025;148:493–505. - PMC - PubMed
    1. Malpetti M, Passamonti L, Rittman T, et al. Neuroinflammation and Tau colocalize in vivo in progressive supranuclear palsy. Ann Neurol. 2020;88:1194–1204. - PMC - PubMed
    1. Malpetti M, Passamonti L, Jones PS, et al. Neuroinflammation predicts disease progression in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2021;92:769–775. - PMC - PubMed

MeSH terms